Ezetimibe/Rosuvastatin Calcium/Candesartan Cilexetil/Amlodipine

依折麦布/瑞舒伐他汀钙/坎地沙坦西酯/氨氯地平

Report date: 2026/03/30 17:02:26

Base Information

Drug NameEzetimibe/Rosuvastatin Calcium/Candesartan Cilexetil/Amlodipine
Drug Alias NameEzetimibe/Rosuvastatin/Candesartan/Amlodipine
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNiemann-Pick C1-like protein 1 inhibitorsCholesterol absorption inhibitorsHMG-CoA reductase inhibitors +[5] 
TargetsNiemann-Pick C1-like protein 1HMG-CoA reductaseAngiotensin II Receptor Type 1 +[4] 
Therapy Area/IndicationsHyperlipoproteinemia Type IIHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes EzetimibeRosuvastatin CalciumCandesartan Cilexetil
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHyundai Pharm. Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHyundai Pharm. Co Ltd
Inactive CompaniesN/A
Active IndicationsHyperlipoproteinemia Type IIHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A